甲状腺功能减退性不孕 中国就医指南

Hypothyroidism-related infertility refers to impaired fertility—either difficulty conceiving or sustaining pregnancy—directly attributable to untreated or inadequately managed primary hypothyroidism. It is not a standalone disease but a clinically significant reproductive complication arising from chronic thyroid hormone deficiency, particularly low circulating thyroxine (T4) and elevated thyroid-stimulating hormone (TSH). Pathogenically, hypothyroidism disrupts the hypothalamic–pituitary–ovarian (HPO) axis: elevated TSH stimulates prolactin secretion, leading to hyperprolactinemia and subsequent suppression of gonadotropin-releasing hormone (GnRH); it also impairs ovarian folliculogenesis, reduces sex hormone-binding globulin (SHBG), alters estrogen metabolism, and contributes to luteal phase defects and anovulation. Autoimmune thyroiditis (Hashimoto’s thyroiditis) is the most common underlying cause in reproductive-aged women, accounting for over 90% of cases. Epidemiologically, subclinical and overt hypothyroidism affects approximately 2–5% of women of childbearing age globally, with prevalence rising to 10–15% among women with unexplained infertility or recurrent pregnancy loss. Risk factors include female sex, age >30 years, personal or family history of autoimmune disorders (e.g., type 1 diabetes, celiac disease), prior thyroid surgery or radioiodine treatment, iodine deficiency or excess, and postpartum thyroiditis. Untreated hypothyroidism-related infertility significantly diminishes quality of life—not only through reproductive distress (emotional burden of infertility, repeated failed cycles, anxiety about miscarriage) but also via persistent fatigue, weight gain, depression, cognitive fog, and sexual dysfunction. Early diagnosis—via sensitive TSH, free T4, and thyroid peroxidase antibody (TPOAb) testing—is critical, as even mild TSH elevation (>2.5 mIU/L) in infertile women correlates with reduced IVF success rates and higher early pregnancy loss. Levothyroxine replacement restores euthyroid status, normalizes gonadotropin pulsatility, improves endometrial receptivity, and enhances oocyte quality. Importantly, fertility outcomes improve markedly when TSH is optimized *before* conception (target <2.5 mIU/L in preconception; <3.0 mIU/L during pregnancy), underscoring the necessity of integrated care between endocrinology and reproductive medicine specialists.

# 甲状腺功能减退性不孕治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：TSH＞4.0 mU/L且TPOAb阳性、月经稀发/排卵障碍、AMH正常、无器质性不孕因素者。

• •基础药物治疗：左甲状腺素钠片（优甲乐）+个体化剂量调整（TSH目标0.4–2.5 mU/L）

• •配套检查费（首年）：甲状腺功能五项（TSH、FT3、FT4、TPOAb、TGAb）180元；性激素六项220元；盆腔超声（含卵泡监测）3次×120元=360元；精液常规200元

二、手术/介入方案

不适用：本病为内分泌代谢性病因，无手术指征；甲状腺切除术或射频消融仅用于合并甲状腺癌/压迫性结节，与不孕无直接因果关系，生殖医学科不开展此类操作。

三、特殊复杂情况处理

耐药/反复流产/合并PCOS者：加用促排卵（来曲唑）+黄体支持（地屈孕酮），年均额外费用2,800–4,500元；复发性生化妊娠者需加查凝血四项、NK细胞活性（1,200元）、子宫内膜容受性检测（ERA，3,600元）。

四、方案快速选择指南

• •预算有限（＜5,000元/年）：优选国产优甲乐+基础监测；
• •备孕急迫（≤6个月）：进口优甲乐+每月卵泡监测+黄体支持；
• •反复失败者：启动全面免疫/凝血/内膜评估，转入生殖内分泌专病门诊。